ACTRN12612000019808尚未招募2 期
Phase II study of nilotinib efficacy in pigmented villo-nodular synovitis / tenosynovial giant cell tumour (PVNS/TGCT)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Age >= 18 years
- •2. Histologically confirmed diagnosis of inoperable progressive or relapsing PVNS/TGCT
- •OR resectable tumour requesting mutilating surgery
- •3. Demonstrated progressive disease in the last 12 months
- •4. At least one measurable site of disease on MRI/CT scan according to RECIST criteria (RECIST version 1.1) based on investigator’s assessment
- •5. WHO Performance status of 0, 1 or 2
- •6. Adequate organ, electrolyte and marrow function, defined as the following: serum bilirubin <=1.5 x ULN; ALT and AST <=2.5 x ULN; serum creatinine <=1.5 x ULN or creatinine clearance >=50 mL/min; absolute neutrophil count (ANC) >=1.5x10^9/L; platelets >=100x10^9/L; serum lipase <=1.5 x ULN; magnesium = lower limit of normal (LLN) and potassium = LLN
- •7. Prior adequate physical examination including weight, height, ECOG PS and vital signs (systolic and
- •diastolic blood pressure, heart rate after at least 5 minutes in supine position)
- •8. Signed written informed consent form
排除标准
- •1. Pregnant or lactating female or female of child-bearing potential not employing adequate contraception during the study and for up to three months following termination of the study
- •2. Known hypersensitivity to nilotinib or to any of the excipients, galactose intolerance, lactase deficiency or glucose-galactose malabsorbtion prior to enrolment
- •3. Acute or chronic uncontrolled liver disease, or severe renal disease
- •4. Impaired cardiac function, including:
- •- LVEF<50% or below the institutional lower limit of the normal range (whichever is higher) as determined by echocardiogram or MUGA scan
- •- History or signs of prior myocardial infarction
- •- History of unstable angina
- •- Congenital long QT prolongation
- •- Personal history of unexplained syncope
- •- QTc interval >= 450 msec on screening ECG
- •- Other clinically significant heart disease (e.g. bradycardia, congestive heart failure or uncontrolled hypertension)
- •5. Patient with family history of long QT syndrome, of unexplained syncope or of unexplained sudden
- •6. Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol e.g. uncontrolled diabetes, active or uncontrolled infection, history of pancreatitis
- •7. History of non-compliance to medical regimens
- •8. Concomitant treatment with medicinal products that induce CYP3A4 (e.g. dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or St. John’s Wort), or that inhibit the CYP3A4 activity (e.g. ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, telithromycin)
- •9. Concomitant treatment with warfarin
- •10. Concomitant treatment with anti-arrhythmic drug (e. g. amiodarone, sotalol, disopyramide, quinidine, procainamide) or medication that prolongs the QT interval (e.g. chloroquine, chlorpromazine, domperidone, droperidol, halofantrine, haloperidol, methadone, pentamidine, pimozide, thioridazine)
- •11. Prior treatment with imatinib except if no progression was demonstrated
研究者
相似试验
进行中（未招募）
1 期
Phase II study of nilotinib efficacy in Pigmented Villo-Nodular Synovitis / Tenosynovial Giant Cell Tumor (PVNS / TGCT) - PVNSPatients with inoperable Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumour (PVNS/TGCT)MedDRA version: 12.1 Level: LLT Classification code 10042875 Term: Synovitis villonodularEUCTR2010-018869-29-FRCENTRE LEON BERARD56
进行中（未招募）
1 期
Phase II study of nilotinib efficacy in Pigmented Villo-Nodular Synovitis / Tenosynovial Giant Cell Tumor (PVNS / TGCT) - PVNSEUCTR2010-018869-29-NLCENTRE LEON BERARD56
进行中（未招募）
1 期
Study of nilotinib efficacy in Pigmented Villo-Nodular Synovitis / Tenosynovial Giant Cell TumorPatients with inoperable Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumour (PVNS/TGCT)MedDRA version: 14.0 Level: LLT Classification code 10042875 Term: Synovitis villonodular System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-018869-29-GBCentre Leon-Berard56
进行中（未招募）
1 期
PHASE II STUDY OF NILOTINIB EFFICACY IN PIGMENTED VILLO-NODULAR SYNOVITIS/ TENOSYNOVIAL GIANT CELL TUMOUR (PVNS/TGCT) - NDPigmented villonodular synovitis (PVNS), also known as tenosynovial giant cell tumour (TGCT)MedDRA version: 9.1Level: LLTClassification code 10042875EUCTR2010-018869-29-ITISTITUTO NAZIONALE PER LA CURA TUMORI56
已完成
2 期
Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)Pigmented Villonodular SynovitisNCT01261429Centre Leon Berard50